Activity Description & Educational Objectives
In this activity, an expert in non–small-cell lung cancer discusses considerations for the selection of patients eligible for maintenance therapy and the evidence base for potential treatment algorithms in this setting. Relevant data discussed by the expert include the influence of patient- and tumor-related factors on the decision to initiate maintenance strategies and new findings on active cytotoxic agents and targeted therapy in this setting.
Upon completion of this activity, participants should be better able to:
- Identify patients with advanced non–small-cell lung cancer (NSCLC) who will derive the greatest benefit from maintenance therapy according to patient and disease characteristics
- Compare and contrast clinical trial data examining the benefits and limitations of continuous versus switch maintenance therapy
- Individualize maintenance therapy for a patient with NSCLC based on disease histology and molecular characteristics of the tumor, clinical features specific to the patient, and the efficacy and safety profile of available maintenance options
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in managing patients with advanced non–small-cell lung cancer.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: November 14, 2012 - November 13, 2013
Time to Complete: 45 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Alan Sandler, MD
Professor of Medicine
Oregon Health & Science University
Alan Sandler, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Boehringer Ingelheim; Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; and Pfizer Inc.
Grant/Research Support from Abraxis; Daiichi Sankyo, Inc.; Eli Lilly and Company; Pfizer Inc.; and Synta Pharmaceuticals Corp.
Speakers Bureau participant with Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; and Pfizer Inc.
Honoraria from Boehringer Ingelheim; Daiichi Sankyo, Inc.; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Imedex; Medical Communications Media, Inc.; Pfizer Inc.; Research To Practice; and Rockpointe Corporation.
Advisory Board for Boehringer Ingelheim; Daiichi Sankyo, Inc.; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; and Pfizer Inc.
Other Financial or Material Support from Boehringer Ingelheim; Daiichi Sankyo, Inc. in the form of Study Meetings. Genentech, Inc. in the form of legal consulting. Eli Lilly and Company; Genentech, Inc.; Medical Communications Media, Inc.; Research To Practice; and Rockpointe Corporation in the form of Content Development. Merrimack Pharmaceuticals Inc.; Pfizer Inc.; and Research To Practice in the form of talks (not Speakers Bureau). Imedex; Medical Communications Media, Inc.; and Research To Practice in the form of panel discussions/symposium/conference.
Christopher Washburn, PhD
PVI, PeerView Institute for Medical Education
Christopher Washburn, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5210-13-T.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.